Pemphigus mouse model as a tool to evaluate various immunosuppressive therapies

Area of Science:

• Immunology
• Dermatology
• Autoimmune Diseases

Background:

• Pemphigus vulgaris (PV) is an autoimmune bullous disease.
• Characterized by immunoglobulin G (IgG) autoantibodies against desmoglein 3 (Dsg3).
• An active mouse model for PV was developed via adoptive transfer of Dsg3(-/-) lymphocytes.

Purpose of the Study:

• To assess the utility of the PV mouse model for evaluating immunosuppressive therapies.
• To identify the benefits and limitations of this model in preclinical drug testing.

Main Methods:

• Adoptive transfer of Dsg3(-/-) lymphocytes to create a PV mouse model.
• Evaluation of immunosuppressive agents using Dsg3 enzyme-linked immunosorbent assay (ELISA) scores, body weight loss, and PV skin lesion scores.
• Preventive protocol testing of cyclophosphamide, azathioprine, cyclosporin A, tacrolimus hydrate, methylprednisolone, and dexamethasone.

Main Results:

• Cyclophosphamide significantly suppressed anti-Dsg3 IgG production, body weight loss, and PV phenotype development.
• Azathioprine, cyclosporin A, and tacrolimus hydrate demonstrated varying degrees of suppressive effects.
• Methylprednisolone and dexamethasone showed no significant therapeutic effects in this model, contrasting with human clinical findings.

Conclusions:

• The developed PV mouse model serves as a valuable tool for evaluating immunosuppressive therapies.
• The model's efficacy in predicting treatment outcomes, particularly for corticosteroids, requires further investigation.
• Understanding the model's advantages and limitations is crucial for future development of novel PV therapeutics.